Phase i study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 2, 2012, Pages 439-446

  Satoh, Taroh ^a,g   Yamada, Yasuhide ^b   Muro, Kei ^c   Hayashi, Hidetoshi ^a   Shimada, Yasuhiro ^b   Takahari, Daisuke ^c   Taku, Keisei ^d   Nakajima, Takako Eguchi ^e   Shi, Xiaojin ^f   Brown, Kathryn H ^f   Boku, Narikazu ^e  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d SHIZUOKA CANCER CENTER   (Japan)

^e ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f ASTRAZENECA   (United Kingdom)

^g OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cediranib; Gastric cancer; Japanese; Phase I; VEGF signalling

Indexed keywords

CAPECITABINE; CEDIRANIB; CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; FATIGUE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HICCUP; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; JAPANESE; LEUKOCYTE COUNT; LEUKOPENIA; LUNG EMBOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; SIGNAL TRANSDUCTION; STEADY STATE; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMATITIS; SYNCOPE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; WOUND INFECTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APPETITE; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FLUOROURACIL; HUMANS; HYPONATREMIA; JAPAN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEUTROPENIA; OXONIC ACID; QUINAZOLINES; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84856736532     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1723-8     Document Type: Article

References (33)

1. GLOBOCAN statistics. 2008. Available at http://globocan.iarc.fr/
2. AM Murad FF Santiago A Petroianu PR Rocha MA Rodrigues M Rausch 1993 Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37 41 8508427 10.1002/1097-0142(19930701)72:1<37:: AID-CNCR2820720109>3.0.CO;2-P 1:STN:280:DyaK3s3osVGqtQ%3D%3D (Pubitemid 23182046)
3. B Glimelius K Hoffman U Haglund O Nyren PO Sjoden 1994 Initial or delayed chemotherapy with best supportive care in advanced gastric cancer Ann Oncol 5 189 190 8186165 1:STN:280:DyaK2c3kt1KrsA%3D%3D (Pubitemid 24062577)
4. S Pyrhonen T Kuitunen P Nyandoto M Kouri 1995 Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587 591 7533517 10.1038/bjc.1995.114 1:STN:280:DyaK2M7os1ertg%3D%3D
5. M Fujii M Kochi T Takayama 2010 Recent advances in chemotherapy for advanced gastric cancer in Japan Surg Today 40 295 300 20339982 10.1007/s00595-009-4148-9 1:CAS:528:DC%2BC3cXjvVGhsL4%3D
6. A Ohtsu Y Shimada S Yoshida H Saito S Seki K Morise M Kurihara 1994 Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan clinical oncology group (JCOG) Eur J Cancer 30A 2091 2093 7857709 10.1016/0959-8049(94)00350-E 1:STN:280:DyaK2M7mtFWntA%3D%3D
7. W Koizumi M Kurihara T Sasai S Yoshida K Morise A Imamura S Akazawa T Betsuyaku S Ohkubo H Takahashi, et al. 1993 A phase II study of combination therapy with 5′-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci Cancer 72 658 662 8334621 10.1002/1097-0142(19930801)72:3<658::AID-CNCR2820720306>3.0.CO;2-K 1:STN:280:DyaK3szisleisQ%3D%3D (Pubitemid 23215247)
8. W Koizumi S Tanabe K Saigenji A Ohtsu N Boku F Nagashima K Shirao Y Matsumura M Gotoh 2003 Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer Br J Cancer 89 2207 2212 14676796 10.1038/sj.bjc.6601413 1:CAS:528:DC%2BD3sXpvVShtbc%3D (Pubitemid 38168001)
9. W Koizumi H Narahara T Hara A Takagane T Akiya M Takagi K Miyashita T Nishizaki O Kobayashi W Takiyama Y Toh T Nagaie S Takagi Y Yamamura K Yanaoka H Orita M Takeuchi 2008 S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215 221 18282805 10.1016/S1470-2045(08)70035-4 1:CAS:528: DC%2BD1cXivVaqtb4%3D
10. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, Hill J, Lehle M, Feyereislova A, Bang Y (2009) Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 27(18S):abst LBA4509
11. N Ferrara 2002 Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications Semin Oncol 29 10 14 12516033 1:CAS:528:DC%2BD3sXlvFSqsQ%3D%3D
12. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim J Berlin A Baron S Griffing E Holmgren N Ferrara G Fyfe B Rogers R Ross F Kabbinavar 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 15175435 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D (Pubitemid 38702844)
13. FF Kabbinavar J Hambleton RD Mass HI Hurwitz E Bergsland S Sarkar 2005 Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J Clin Oncol 23 3706 3712 15867200 10.1200/JCO.2005.00.232 1:CAS:528:DC%2BD2MXlslWntro%3D
14. LB Saltz S Clarke E Diaz-Rubio W Scheithauer A Figer R Wong S Koski M Lichinitser TS Yang F Rivera F Couture F Sirzen J Cassidy 2008 Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013 2019 18421054 10.1200/JCO.2007.14.9930 1:CAS:528:DC%2BD1cXlvFaqs7g%3D
15. A Sandler R Gray MC Perry J Brahmer JH Schiller A Dowlati R Lilenbaum DH Johnson 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550 17167137 10.1056/NEJMoa061884 1:CAS:528:DC%2BD28XhtlWqsbzI (Pubitemid 44917502)
16. Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Wedge SR, Jürgensmeier JM (2007) Inhibition of VEGF-C-induced VEGFR-3 activity and lymphatic endothelial cell function by the tyrosine kinase inhibitor AZD2171. Proc Am Assoc Cancer Res 48:abst 2999
17. SR Wedge J Kendrew LF Hennequin PJ Valentine ST Barry SR Brave NR Smith NH James M Dukes JO Curwen R Chester JA Jackson SJ Boffey LL Kilburn S Barnett GH Richmond PF Wadsworth M Walker AL Bigley ST Taylor L Cooper S Beck JM Jürgensmeier DJ Ogilvie 2005 AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer Cancer Res 65 4389 4400 15899831 10.1158/0008-5472.CAN-04- 4409 1:CAS:528:DC%2BD2MXktlSmtLs%3D (Pubitemid 40775678)
18. N Yamamoto T Tamura N Yamamoto K Yamada Y Yamada H Nokihara Y Fujiwara T Takahashi H Murakami N Boku K Yamazaki TA Puchalski E Shin 2009 Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors Cancer Chemother Pharmacol 64 1165 1172 19308410 10.1007/s00280-009-0979-8 1:CAS:528:DC%2BD1MXhtVWhsrjN
19. J Drevs P Siegert M Medinger K Mross R Strecker U Zirrgiebel J Harder H Blum J Robertson JM Jürgensmeier TA Puchalski H Young O Saunders C Unger 2007 Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors J Clin Oncol 25 3045 3054 17634482 10.1200/JCO.2006.07.2066 1:CAS:528:DC%2BD2sXptlGrsbo%3D (Pubitemid 47218051)
20. SA Laurie I Gauthier A Arnold FA Shepherd PM Ellis E Chen G Goss J Powers W Walsh D Tu J Robertson TA Puchalski L Seymour 2008 Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group J Clin Oncol 26 1871 1878 18398152 10.1200/JCO.2007.14.4741 1:CAS:528:DC%2BD1cXmsFemtr0%3D
21. E Chen D Jonker I Gauthier M Maclean J Wells J Powers L Seymour 2009 Phase I study of cediranib in combination with oxaliplatin and infusional 5-fluorouracil in patients with advanced colorectal cancer Clin Cancer Res 15 1481 1486 19228749 10.1158/1078-0432.CCR-08-0761 1:CAS:528:DC%2BD1MXitVOktLY%3D
22. G Goss FA Shepherd S Laurie I Gauthier N Leighl E Chen R Feld J Powers L Seymour 2009 A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group Eur J Cancer 45 782 788 19091548 10.1016/j.ejca.2008.10.022 1:CAS:528:DC%2BD1MXisl2rsLo%3D
23. LoRusso P, Shields AF, Gadgeel S, Vaishampayan U, Guthrie, T, Puchalski T, Xu J, Liu Q (2010) Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study. Invest New Drugs. doi: 10.1007/s10637-010-9484-5. Epub ahead of print
24. GD Goss A Arnold FA Shepherd M Dediu TE Ciuleanu D Fenton M Zukin D Walde F Laberge MD Vincent PM Ellis SA Laurie K Ding E Frymire I Gauthier NB Leighl C Ho J Noble CW Lee L Seymour 2010 Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study J Clin Oncol 28 49 55 19917841 10.1200/JCO.2009.22.9427 1:CAS:528:DC%2BC3cXhtF2ku7Y%3D
25. JD Robertson NA Botwood ML Rothenberg H-J Schmoll 2009 Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III Clin Colorectal Cancer 8 59 60 19203899 10.3816/CCC.2009.n.010 1:CAS:528:DC%2BD1MXjtVylsrY%3D
26. AstraZeneca (2011) Global policy: bioethics. Available at http://www.astrazeneca.com/Responsibility/Code-policies-standards/ Policiesstandards
27. P Therasse 2002 Measuring the clinical response. What does it mean? Eur J Cancer 38 1817 1823 12204662 10.1016/S0959-8049(02)00182-X 1:STN:280: DC%2BD38vkslyntw%3D%3D (Pubitemid 35256090)
28. vanCruijsen H, Voest EE, van Herpen CML, Hoekman K, Witteveen PO, Tjin-A-Ton ML, Punt CJ, Puchalski T, Milenkova T, Giaccone G (2006) Phase I evaluation of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in combination with gefitinib, in patients with advanced tumors. J Clin Oncol 24(S18):abst 3017
29. SS Lee JL Lee MH Ryu HM Chang TW Kim HJ Kang WK Kim JS Lee YK Kang 2007 Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis Jpn J Clin Oncol 37 30 37 17272321 10.1093/jjco/hyl134 (Pubitemid 47096440)
30. JO Lee KW Lee DY Oh JH Kim SA Im TY Kim YJ Bang 2009 Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma Ann Oncol 20 1402 1407 19502532 10.1093/annonc/mdp010 1:STN:280:DC%2BD1MrjtlOmtQ%3D%3D
31. T Schulz-Utermoehl M Spear CR Pollard C Pattison H Rollison S Sarda M Ward N Bushby A Jordan M Harrison 2010 In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology Drug Metab Dispos 38 1688 1697 20634336 10.1124/dmd.110.033159 1:CAS:528:DC%2BC3cXht1eisLjP
32. Kim C, Lee J-L, Choi YH, Kang BW, Ryu M-H, Chang HM, Kim TW, Kang Y-K (2011) Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs. doi: 10.1007/s10637-010-9531-2. Epub ahead of print
33. Kang Y, Ohtsu A, Van Cutsem E, Rha SY, Sawaki A, Park P, Lim H, Wu J, Langer B, Shah MA (2010) AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol 28(18S):abst LBA4007